In late February, Cynata received a notice of Decision to Grant from the State Intellectual Property Office of the People’s Republic of China (SIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology (scroll to after the table):
With COVID shining a light on the importance of innovation in medicine with a focus on unmet needs, read Ross’ view on the work being done to improve the effectiveness of drugs and treatments, and to reduce their side effects:
CEO Dr Ross Macdonald joined ausbiz to discuss the development and the outlook for Cynata in 2022 following the receipt of a patent from Japan, the world’s second largest stem cell market.
Providing hope for people with diabetic foot ulcers (DFU), Cynata’s Phase I trial of CYP‑006TK has commenced and is now open for patient enrolment:
Investing in medical research projects with the potential to deliver better health outcomes to more Australians is a government priority with the Morrison government investing more than $25m through the Biomedical Translation Fund three, in cutting-edge companies including Cynata: